2025年地夫可特最新价格是多少钱一盒？

Introduction: Deflazacort is approved in the United States for the treatment of Duchenne muscular dystrophy. Compared with other glucocorticoid drugs, its advantages include no restrictions on the stage of the patient's disease, a wider range of applicable people, lower incidence of adverse reactions such as weight gain, better patient compliance, and more significant overall treatment effects. Its price has always been a focus of attention.

How much does a box of deflazacort cost in 2025?

The latest price in 2025 may vary due to drug versions, exchange rate changes, purchase channels and other factors. The German version of Deflazacort is available in a box of 6mg*100 tablets, and the price of a box is approximately US$82. The Indian version of deflazacort is available in a box of 6mg*100 tablets, and the price of a box is about US$42.
The above prices are for reference only. The specific price of deflazacort varies by region and sales channel. Patients can purchase it through hospital pharmacies or large chain pharmacies.

Precautions for deflazacort

Gastrointestinal perforation

Patients with certain gastrointestinal diseases, such as active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and nonspecific ulcerative colitis, are at increased risk of gastrointestinal perforation while taking deflazacort, and symptoms of gastrointestinal perforation, such as peritoneal puncture, may be masked in patients receiving deflazacort.

Behavioral and Mood Disorders

Potentially serious psychiatric adverse reactions may occur with deflazacort, with symptoms usually occurring within days or weeks of starting treatment and may be dose-related. Although drug treatment may be needed, these reactions may improve with dose reduction or discontinuation of the drug.
Psychiatric adverse reactions often involve hypomanic or manic symptoms during treatment, such as euphoria, insomnia, mood swings, and depressive episodes after treatment is discontinued. Inform patients or caregivers of the possibility of behavioral and mood changes and encourage them to seek medical attention if they develop psychiatric symptoms, especially if depression or suicidal ideation is suspected.

Effects on bones

Deflazacort reduces bone formation and increases bone absorption through its effects on calcium regulation (i.e. reducing absorption and increasing excretion) and inhibiting osteoblast function. Long-term use may cause reduced bone mineral density, femoral head necrosis, etc.

Deflazacort Pharmacokinetics

Absorption

After oral administration in the fasted state, the median Tmax of deflazacort tablets is approximately 1 hour (range 0.25- 2 hours), the bioavailability of deflazacort tablets is similar to that of the oral suspension, and administration of deflazacort with food or crushed in applesauce does not affect the absorption and bioavailability of deflazacort.

Distribution

The protein binding rate of the active metabolite of Fucort is approximately 40%.

Metabolism

Deflazacort is rapidly converted to the active metabolite 21-desDFZ by esterases after oral administration. 21-desDFZ is further metabolized by CYP3A4 to several other inactive metabolites, including 6β-hydroxy-21-desacetyl deflazacort.

Excretion

Urine excretion is the main route of elimination of deflazacort (accounting for approximately 68% of the dose), and elimination is almost complete within 24 hours after administration, with 21-desDFZ accounting for 18% of the drug eliminated in the urine.